Abstract
Osteosarcoma (OS) metastatic disease is resistant to conventional chemotherapy. Tumor resistance to chemotherapy has been one of the major areas of concern to clinicians and the topic of many laboratory investigators. Evaluation of mechanisms implicated in OS lung metastasis resistance to chemotherapy has been the focus of some of our most recent work. We have previously demonstrated the therapeutic efficacy of aerosol gemcitabine (GCB) in OS lung metastases. However, a subset of cells fails to respond to GCB treatment and persists as isolated lung metastases in vivo. Autophagy, a physiological mechanism that supports nutritional deprivation under stressful conditions, has been implicated in tumor resistance to chemotherapy. We demonstrated the induction of autophagy by GCB in LM7 metastatic human OS cells and K7M3 metastatic murine OS cells. Inhibition of autophagy resulted in increased sensitivity to GCB in LM7 cells. By contrast, inhibiting autophagy in K7M3 cells decreased GCB sensitivity. Defining the role autophagy plays in chemotherapy response in different tumor types has become of greater importance in order to identify the best suitable therapeutic approach. In this chapter, we summarize some of the most recent work related to autophagy in OS, identify some of the known mechanisms, and address the different roles autophagy plays in chemotherapy response.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gordon N, Kleinerman ES (2009) The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 152:497–508. doi:10.1007/978-1-4419-0284-9_29
Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P (2009) Major cell death pathways at a glance. Microbes Infect 11(13):1050–1062. doi:10.1016/j.micinf.2009.08.013
Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16):2891–2906. doi:10.1038/sj.onc.1207521
Shen HM, Codogno P (2011) Autophagic cell death: Loch Ness monster or endangered species? Autophagy 7(5):457–465
Aredia FGL, Giansanti V, Scovassi AI (2012) Autophagy and cancer. Cells 1(3):520–534
Sun Y, Peng ZL (2009) Programmed cell death and cancer. Postgrad Med J 85(1001):134–140. doi:10.1136/pgmj.2008.072629
Yang ZJ, Chee CE, Huang S, Sinicrope FA (2011) The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10(9):1533–1541. doi:10.1158/1535-7163.MCT-11-0047
Liu EY, Ryan KM (2012) Autophagy and cancer—issues we need to digest. J Cell Sci 125(Pt 10):2349–2358. doi:10.1242/jcs.093708
Huber A, Rubio A, Loewith RJ (2009) Mammalian target of rapamycin signaling and cancer treatment. Cancer Chemother Rev 4(4):210–223
Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS (2009) MTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strat 6(2):47–55, http://dx.doi.org/10.1016/j.ddstr.2009.12.001
Kang R, Zeh HJ, Lotze MT, Tang D (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18(4):571–580. doi:10.1038/cdd.2010.191
Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122(6):927–939. doi:10.1016/j.cell.2005.07.002
Furuya N, Yu J, Byfield M, Pattingre S, Levine B (2005) The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy 1(1):46–52
Ciechomska IA, Goemans GC, Skepper JN, Tolkovsky AM (2009) Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene 28(21):2128–2141. doi:10.1038/onc.2009.60
Boya P, Kroemer G (2009) Beclin 1: a BH3-only protein that fails to induce apoptosis. Oncogene 28(21):2125–2127. doi:10.1038/onc.2009.83
Sun Q, Fan W, Chen K, Ding X, Chen S, Zhong Q (2008) Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 105(49):19211–19216. doi:10.1073/pnas.0810452105
Lorin S, Borges A, Dos Santos LR, Souquere S, Pierron G, Ryan KM, Codogno P, Djavaheri-Mergny M (2009) c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated ewing sarcoma cells. Cancer Res 69(17):6924–6931, http://dx.doi.org/10.1158/0008-5472.CAN-09-1270
Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T, Jaakkola PM (2009) Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 28(3):334–344. doi:10.1038/onc.2008.392
Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S (2012) Hypoxia-induced autophagy: a new player in cancer immunotherapy? Autophagy 8(4):704–706. doi:10.4161/auto.19572
Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J (2010) The RB-E2F1 pathway regulates autophagy. Cancer Res 70(20):7882–7893. doi:10.1158/0008-5472.can-10-1604
Coupienne I, Fettweis G, Piette J (2011) RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg Med 43(7):557–564. doi:10.1002/lsm.21088
Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D, Ni J (2012) Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8(2):275–277. doi:10.4161/auto.8.2.18940
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D (2012) HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72(1):230–238. doi:10.1158/0008-5472.can-11-2001
Wong W (2013) Inhibit autophagy, STAT! Sci Signal 6(256):ec4, http://dx.doi.org/10.1126/scisignal.2003913
Roy S, Debnath J (2010) Autophagy and tumorigenesis. Semin Immunopathol 32(4):383–396. doi:10.1007/s00281-010-0213-0
Chen N, Debnath J (2010) Autophagy and tumorigenesis. FEBS Lett 584(7):1427–1435. doi:10.1016/j.febslet.2009.12.034
Pardo R, Lo Re A, Archange C, Ropolo A, Papademetrio DL, Gonzalez CD, Alvarez EM, Iovanna JL, Vaccaro MI (2010) Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology 10(1):19–26. doi:10.1159/000264680
Eskelinen EL (2011) The dual role of autophagy in cancer. Curr Opin Pharmacol 11(4):294–300. doi:10.1016/j.coph.2011.03.009
Akin D, Law B, Progulske-fox A, Dunn WA (2009) Identification of compounds that enhance and suppress autophagy. Autophagy 5(6):910–911
Notte A, Leclere L, Michiels C (2011) Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 82(5):427–434. doi:10.1016/j.bcp.2011.06.015
Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101(52):18030–18035. doi:10.1073/pnas.0408345102
Periyasamy-Thandavan S, Jiang M, Schoenlein P, Dong Z (2009) Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 297(2):F244–F256. doi:10.1152/ajprenal.00033.2009
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16(1):3–11. doi:10.1038/cdd.2008.150
Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr (2010) Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980–4990. doi:10.1002/cncr.25426
Seibenhener ML, Geetha T, Wooten MW (2007) Sequestosome 1/p62—more than just a scaffold. FEBS Lett 581(2):175–179. doi:10.1016/j.febslet.2006.12.027
Komatsu M, Ichimura Y (2010) Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 584(7):1374–1378. doi:10.1016/j.febslet.2010.02.017
Ichimura Y, Komatsu M (2010) Selective degradation of p62 by autophagy. Semin Immunopathol 32(4):431–436. doi:10.1007/s00281-010-0220-1
Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85(9):1219–1226. doi:10.1016/j.bcp.2013.02.017
Doroshow JH (2013) Overcoming resistance to targeted anticancer drugs. N Engl J Med 369(19):1852–1853. doi:10.1056/NEJMe1311325
Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35–48. doi:10.1159/000086183
Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76. doi:10.1007/978-1-60761-416-6_4
Rufini A, Melino G (2011) Cell death pathology: the war against cancer. Biochem Biophys Res Commun 414(3):445–450, http://dx.doi.org/10.1016/j.bbrc.2011.09.110
Meschini S, Condello M, Marra M, Formisano G, Federici E, Arancia G (2007) Autophagy-mediated chemosensitizing effect of the plant alkaloid voacamine on multidrug resistant cells. Toxicol In Vitro 21(2):197–203. doi:10.1016/j.tiv.2006.09.007
Meschini S, Condello M, Calcabrini A, Marra M, Formisano G, Lista P, De Milito A, Federici E, Arancia G (2008) The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy 4(8):1020–1033
Dhule SS, Penfornis P, Frazier T, Walker R, Tan G, He J, John V, Pochampally R (2011) Curcumin in cyclodextrin in liposome as a delivery vehicle against osteosarcoma. Cancer Res http://dx.doi.org/10.1158/1538-7445.AM2011-4227
Li X, Wu WK, Sun B, Cui M, Liu S, Gao J, Lou H (2011) Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl Pharmacol 251(2):146–154. doi:10.1016/j.taap.2010.12.007
Ma D, Tremblay P, Mahngar K, Collins J, Hudlicky T, Pandey S (2011) Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin. PLoS One 6(12). http://dx.doi.org/10.1371/journal.pone.0028780
Bechara A, Pereira GJS, Paredes-Gamero EJ, Barbosa CMV, Nascimento FD, Hirata H, Caires ACF, Smaili SS, Bincoletto C (2011) Autophagy and apoptosis modulation in osteosarcoma cells exposed to a new palladacycle compound. Basic Clin Pharmacol Toxicol 109:59, http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
Calvaruso G, Pellerito O, Notaro A, Giuliano M (2012) Cannabinoid-associated cell death mechanisms in tumor models (review). Int J Oncol 41(2):407–413, http://dx.doi.org/10.3892/ijo.2012.1476
Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, Cao Q (2010) The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 293(2):167–174. doi:10.1016/j.canlet.2010.01.006
Urquiza L, Zalacain M, Marrodan L, Odero MD, Lecanda F, Gomez-Manzano C, Fueyo J, Sierrasesumaga L, Patino-Garcia A, Alonso MM (2011) Enhancing autophagy as a novel approach to target osteosarcoma: combination of oncolytic adenovirus and chemotherapy. Cancer Res. http://dx.doi.org/10.1158/1538-7445.AM2011-5402
Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68(19):7966–7974, http://dx.doi.org/10.1158/0008-5472.CAN-08-1333
Zhang Z, Shao Z, Xiong L, Che B, Deng C, Xu W (2009) Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity. J Huazhong Univ Sci Technolog Med Sci 29(6):737–740. doi:10.1007/s11596-009-0613-3
Gordon N, Kleinerman ES (2010) Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 23(4):189–196. doi:10.1089/jamp.2009.0812
Santiago-O’Farril (2013) in progress
Acknowledgements
We are grateful to Amy A. Sisson from the UT MD Anderson Research Medical library for her clerical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
O’Farrill, J.S., Gordon, N. (2014). Autophagy in Osteosarcoma. In: Kleinerman, M.D., E. (eds) Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, vol 804. Springer, Cham. https://doi.org/10.1007/978-3-319-04843-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-04843-7_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-04842-0
Online ISBN: 978-3-319-04843-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)